Intravitreal Bevacizumab in acute Branch Retinal Vein Occlusion(BRVO)

Outcoms of intravitreal injection of bevacizumab in patients with acute Branch retinal Vein Occlusion(BRVO)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201106214856N2

Enrollment

Registered

2011-07-03

Start date

2011-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch Retinal Vein occlusion. Other retinal vascular occlusions

Interventions

Intravitreal single dose injection of 1.25 mg Bevacizumab(Avastin) at the begining of study for all 22 patients..

Treatment - Drugs

Intravitreal single dose injection of 1.25 mg Bevacizumab(Avastin) at the begining of study for all 22 patients.

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion: Patients with initial diagnose of branch retinal vein occlusion(BRVO) based on examination with Slit Lamp; Less than one week of symptoms onset. Exclusion: Other pathologies of retinal vessels beside BRVO based on flurcein angiography(FA); Patients that have recevied any medication for BRVO.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Macular Thickness. Timepoint: Befor injection and 1,3 and 6 to 16 monthes after injection. Method of measurement: Optical Coherence Tomography(OCT).	—

Secondary

Measure	Time frame
Visual accuity. Timepoint: Before injection and 1,3 and 6 to 16 monthes after injection. Method of measurement: Snelen Chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYaser Bolouki Moghaddam

General Practitioner, Department of ophthalmology, Baqiyatallah Hospital, Baqiyatallah University of

moghaddam882@yahoo.com+98 21 8216 2432

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026